Research Article

Combined Effects of Aerobic Exercise and Diet on Lipids and Lipoproteins in Overweight and Obese Adults: A Meta-Analysis

George A. Kelley,¹ Kristi S. Kelley,¹ Susan Roberts,² and William Haskell³

¹ Department of Community Medicine, School of Medicine, West Virginia University, P.O. Box 9190, Morgantown, WV 26506-9190, USA

² Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA 02111-1524, USA

³ Prevention Research Center, Stanford University, Palo Alto, CA 94305-2004, USA

Correspondence should be addressed to George A. Kelley, gkelley@hsc.wvu.edu

Received 18 August 2011; Accepted 1 December 2011

Academic Editor: Eliot Brinton

Copyright © 2012 George A. Kelley et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This study used the aggregate data meta-analytic approach to determine the combined effects of aerobic exercise and diet on lipids and lipoproteins in overweight and obese adults. Twelve studies representing 859 men and women (443 intervention, 416 control) were included. Using random-effects models, statistically significant, intervention minus control reductions were found for TC (−12.8 mg/dL, 95% CI, −19.9 to −5.7), TC:HDL-C (−0.5 mg/dL, 95% CI, −0.8 to −0.1), LDL-C (−6.8 mg/dL, 95% CI, −11.8 to −1.8), and TG (−13.1 mg/dL, 95% CI, −21.2 to −5.0) but not HDL-C (−0.4 mg/dL, 95% CI, −2.3 to 1.6). Results remained robust when adjusted for publication bias, deleting each study from the model once, and collapsing results for multiple groups from the same study into one effect size. These findings suggest that concurrent aerobic exercise and diet improve TC, LDL-C, TC:HDL-C, and TG, but not HDL-C, in overweight and obese adults.

1. Introduction

Overweight and obesity is a major public health problem worldwide. For example, the World Health Organization reported that the global prevalence of overweight and obesity in adults, defined as a body mass index (BMI) ≥ 25 kg/m², is approximately 2 billion, and by the year 2015, will increase to approximately 3 billion [1]. In the United States (US), an estimated 68% of adults are either overweight or obese [2]. Less-than-optimal concentrations of lipids and lipoproteins, a major risk factor for cardiovascular disease [3], are more prevalent among overweight and obese versus normal weight adults. For example, using data from the United States Behavioral Risk Factor Surveillance System Survey, the age-adjusted prevalence of elevated total cholesterol (TC) was approximately 10% to 16% greater among overweight and obese versus normal weight adults [4]. Aerobic exercise combined with diet is commonly recommended for improving and maintaining optimal concentrations of lipids and lipoproteins in overweight and obese adults [5]. However,

previous randomized controlled trials addressing the combined effects of aerobic exercise and diets aimed at improving TC, high-density lipoprotein cholesterol (HDL-C), ratio of TC:HDL-C, low-density lipoprotein cholesterol (LDL-C), and triglycerides (TG) in adults have reached conflicting conclusions [6–17]. For example, using the vote-counting approach [18], the percentage of outcomes reported as statistically significant has been underwhelming: TC (43%), HDL-C (8%), TC:HDL-C (43%), LDL-C (25%), TG (46%). The between-study discrepancy in these findings may be related to such things as age, gender, baseline lipid and lipoprotein levels, intervention characteristics, changes in body composition, aerobic fitness, and nutrient intake. However, reliance on the vote-counting approach can be extremely misleading [18]. Meta-analysis is a quantitative approach for combining the results of studies. The strengths of meta-analysis include (1) increased power, (2) improved estimates of effect size, and (3) the potential to resolve disagreements between studies [19]. Thus, given the aforementioned conflicting findings, the purpose of this study

was to use the meta-analytic approach to determine the combined effects of aerobic exercise and diet on lipid and lipoprotein concentrations in overweight and obese adults.

2. Methods

2.1. Data Sources. Studies for the current meta-analysis were retrieved from a large in-house aerobic exercise and diet database that includes 1401 citations (all references available upon request). The initial database was developed by searching nine electronic databases, (PubMed, EMBASE, CINAHL, Cochrane Central Register of Controlled Trials, SportDiscus, Dissertation Abstracts International, Physiotherapy Evidence Database (PEDRO), Latin American and Caribbean Health Sciences Database (LILACS), Web of Science), cross-referencing from retrieved studies, and expert review (SR, WH).

Per recent PRISMA recommendations [20], the search query used for one of the databases included in the original search (PubMed) is shown as follows.

User Query for PubMed Search.

```
("1955/01/01" [PDAT]: "2009/05/01" [PDAT]) AND
(("exercise" [MeSH Terms] OR
"exercise" [All Fields]) AND ("diet" [MeSH Terms]
OR "diet" [All Fields]) AND
("lipids" [MeSH Terms] OR "lipids" [All Fields]) OR
("exercise" [MeSH Terms] OR
"exercise" [All Fields]) AND ("diet" [MeSH Terms]
OR "diet" [All Fields]) AND
("cholesterol" [MeSH Terms] OR "cholesterol" [All
Fields])) AND
("humans" [MeSH Terms] AND Randomized Con-
trolled Trial[ptyp] AND "adult" [MeSH Terms]).
```

2.2. Study Selection. The inclusion criteria for this study were as follows: (1) randomized trials with a comparative control group (no intervention, usual care, attention control), (2) aerobic exercise along with any diet considered to improve lipids and lipoproteins (low saturated fat, caloric restriction, etc.), (3) combined aerobic exercise and diet intervention ≥ 4 weeks, (4) adult humans ≥ 18 years of age, (5) all participants considered to have a BMI ≥ 25 kg/m², (6) published studies, including dissertations and Master's theses, (7) studies published in any language, (8) studies published between January 1, 1955 and May 1, 2009, and (9) assessment of one or more of the following lipids and lipoproteins: TC, HDL-C, TC:HDL-C, non-HDL-C, LDL-C, and TG. The year 1955 was chosen as the starting point for potential inclusion of studies since this appeared to be the first time that an intervention on aerobic exercise and diet had been reported [21]. Aerobic exercise was defined according to the recent Physical Activity Guidelines Activity Report, that is, "Exercise that primarily uses the aerobic energy-producing systems, can improve the capacity and efficiency of these systems, and is effective for improving cardiorespiratory endurance" [22].

Any studies not meeting all the criteria above were excluded from the study. All studies were selected by the first two authors. Discrepancies were resolved by consensus.

2.3. Data Abstraction. Electronic codebooks that could record up to 205 items per study were developed prior to data abstraction. The major categories that were coded included (1) study characteristics, (2) participant characteristics, (3) aerobic exercise and diet characteristics, and (4) changes in primary and secondary outcomes. The first two authors coded all studies independent of each other and then reviewed each item for accuracy and consistency. Disagreements were discussed until agreement could be reached.

Because of the lack of empirical evidence [23, 24], including validity [25, 26], to support the use of quality scales, the risk of bias assessment tool recently recommended by the Cochrane Collaboration was used [27]. Briefly, this instrument assesses bias across six domains: (1) sequence generation, (2) allocation concealment, (3) blinding to group assignment, (4) incomplete outcome data, (5) selective outcome reporting, and (6) other potential bias [27]. Each domain is categorized as having either a high, low, or unclear risk of bias [27]. Assessment for the potential risk of bias was limited to the study's primary outcomes. Given the methods used to assess lipids and lipoproteins versus a more qualitative measure such as self-reported quality of life, all studies were considered to be at a low risk of bias for blinding. Other potential bias included whether participants had been taking part in a regular exercise program, as defined by the study authors, prior to study enrollment. The first two authors conducted all bias assessments independent of each other and then met and reviewed every item for agreement. Disagreements were discussed until consensus could be reached.

2.4. Statistical Analysis

2.4.1. Calculation of Effect Sizes from Each Study. The primary outcomes of interest were TC, HDL-C, TC:HDL-C, non-HDL-C, LDL-C, and TG. The original metric (milligrams per deciliter) was chosen as the effect size (ES) for analysis. While somewhat arbitrary, at least 5 ESs per variable were required in order to be included in the meta-analysis. The ES for each lipid and lipoprotein variable for each group from each study were calculated by subtracting the change score difference in the aerobic exercise and diet group from the change score difference in the control group. The variance for each ES was calculated from the pooled standard deviations of change scores in the intervention (aerobic exercise and diet) and control groups. If change score standard deviations were not available, they were calculated from 95% confidence intervals or before and after standard deviation values according to previously developed procedures [28]. Each ES was then weighted by the inverse of its variance. Missing primary outcome data were requested and received from the authors of two studies [7, 8].

Secondary outcomes included changes in body weight, BMI in kg/m², maximum oxygen consumption (VO_{2max} mL·kg⁻¹·min⁻¹), and intake of kilocalories,

carbohydrates, total fat, saturated fat, and cholesterol. A lack of data were available for the inclusion of non-HDL-C (dispersion statistics), percent body fat, lean body mass, waist circumference, energy expenditure, protein, fiber, and transfat.

2.4.2. Pooled Estimates of ESs for Primary and Secondary Outcomes. Random-effects, method of moments models that incorporates heterogeneity in the analysis, were used to pool primary and secondary outcomes [29]. The sole focus on random-effects models is based on the fact that random-effects models assume that the true effect size varies across studies while fixed-effects models assume one true effect size, the latter of which is almost never the case [30]. Multiple groups from the same study were analyzed separately as well as after collapsing groups so that one ES represented each study. Two-tailed 95% confidence intervals that did not cross zero were considered to be statistically significant. Effect sizes with standardized residuals greater than 3 were deleted from the final model.

Heterogeneity was assessed using Cochran's Q statistic and an alpha value for statistical significance of 0.10 [31]. Between-study inconsistency of ES was examined using an extension of the Q statistic, I^2 [32]. Generally, I^2 values of 25% to <50%, 50% to <75%, and $\geq 75\%$ are considered to represent small, medium, and large amounts of inconsistency [32].

Publication bias was examined using the data imputation approach of Duval and Tweedie [33]. In addition, the influence of each study on the overall results was examined by deleting each study from the model once. Cumulative meta-analysis, ranked by year, was used to examine results over time [34] while 95% prediction intervals were used to determine treatment effects in a new trial [35]. Simple, random effects metaregression (method-of-moments approach) was conducted to examine the association between changes in lipids and lipoproteins and age, gender, baseline lipid and lipoprotein levels, length of the intervention in weeks and changes in body weight, BMI, $VO_{2\max}$ in $\text{mL}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$, kilocalories, total fat, saturated fat, and cholesterol. In addition, meta-regression was conducted in order to examine the relationship between gender and changes in body weight, total kilocalories, total fat, saturated fat and cholesterol consumed. Nonoverlapping 95% confidence intervals for the slope (β_1) were considered statistically significant. With the exception of the length of the intervention, we were unable to conduct any type of analyses with respect to dose-response associations.

Descriptive statistics were generated using PASW, version 18.0, reliability using Excel 2007 and all meta-analytic analyses using Comprehensive Meta-Analysis, version 2.2. Data are reported as mean $\pm$ standard deviation ($\bar{X} \pm \text{SD}$), medians (Mdn), percentages (%) and 95% confidence intervals (95% CI).

3. Results

3.1. Study Characteristics. Twelve studies representing up to 28 groups (14 intervention, 14 control) and 859 men and

women (443 intervention, 416 control) were available for pooling [6–17]. A flow chart that describes the search process is shown in Figure 1 while a general description of the studies is shown in Table 1. The number of groups was greater than the number of studies because two studies reported data partitioned by gender [10, 17]. Dropout rates for the 11 groups in which data were available ranged from 0% to 63.6% in the intervention groups ($\bar{X} \pm \text{SD}$, 13.5 ± 17.7 , Mdn, 9) and 0% to 40% in the control groups ($\bar{X} \pm \text{SD}$, 13.3 ± 13.3 , Mdn, 9). Little information was provided for the reasons why participants dropped out of the studies. The final number of participants in which data were pooled ranged from 4 to 137 in the exercise and diet groups ($\bar{X} \pm \text{SD}$, 32 ± 32 , Mdn, 23) and 6 to 140 in the control groups ($\bar{X} \pm \text{SD}$, 30 ± 33 , Mdn, 23). Nine of 12 studies (75%) reported receiving some type of external funding [6–8, 10, 13–17]. Eleven of the 12 included studies (91.7%) were published in journals [6–11, 13–17] while 1 was a dissertation [12]. All studies were published in the English language between 1986 and 2006 [6–17]. With respect to statistical analysis, all studies appeared to use the per-protocol approach in the analysis of their data [6–17]. Five of 12 studies (41.7%) reported some type of matching procedure [6, 8, 13, 14, 17]. This included stratification by either bodyweight [8], race (African-American and other) [14], sex [17], sex and degree of insulin sensitivity [13], or type of medication (insulin or oral agents and diet therapy) [6]. None of the studies used a crossover design [6–17].

3.2. Risk of Bias Assessment. Overall results for risk of bias are shown in Figure 2. As can be seen, all studies appeared to use appropriate procedures for sequence generation [6–17], but only one reported an acceptable process for allocation concealment [14]. Given the methods used for the assessment of lipid and lipoprotein concentrations, all studies were considered to be at a low risk of bias for blinding [6–17]. Less than half the studies were considered to be at a low risk of bias with respect to incomplete data [8, 9, 11, 14]. Given the absence of a study protocol identification number, the risk of bias for incomplete outcome reporting was determined to be unclear across all studies [6–17]. The majority of studies (66.7%) were considered to be at a low risk of bias with regards to participants engaging in a regular exercise program prior to study enrollment [7–10, 12, 13, 15, 17].

3.3. Participant Characteristics. A description of the characteristics of participants for each study is shown in Table 1 while a group description is shown in Table 2. Seven studies included men and women [6, 8, 10, 13, 14, 16, 17] with two reporting data separately according to gender [10, 17]. Another four studies were limited to women [9, 11, 12, 15] while one was limited to men [7]. The number of men and women could not be calculated because of missing data from some studies. For the five studies reporting data on race/ethnicity [6, 9, 11, 13, 14], one each reported that participants were either African-American [6], Caucasian [13], Japanese [11], or Latino (90% Mexican-American and 10% Mexican) [9]. Another study reported that 68% of the participants in the intervention group and 57% in the control group were black [14].

TABLE 1: General characteristics of studies.

Study	Country	Group characteristics*	Exercise intervention	Diet intervention	Lipid assessment
Agurs-Collins et al. (1997) [6]	USA	64 overweight African-American men and women with type 2 diabetes, 55–79 yrs age, assigned to an exercise and diet ($n = 32$) or usual care ($n = 32$) group	12 wks of 20 min of supervised low-impact aerobic exercise 1x wk; encouraged to exercise 2x wk and increase physical activity in daily routines	Carbohydrate, 55%–60% of kcal; protein 12–20%; fat, <30%; weight loss of 4.5 kg at ≤ 0.9 kg per week using the Exchange Lists for Meal Planning program	TC, HDL, TC/HDL, LDL, TG after a 12 hr overnight fast; LDL estimated using the Friedwald formula
Anderssen et al. (2005) [7]	Norway	285 drug-treated, sedentary, overweight hypertensive men, 40–75 yrs of age, assigned to a placebo and lifestyle intervention ($n = 142$) or placebo and usual care ($n = 143$) group	209 wks of supervised aerobic exercise 2x wk; home-based individualized aerobic activity program	Individualized to reduce caloric intake, saturated fat and sugar, and to increase intake of fruit, vegetables, complex carbohydrates, fish, and fish products	TC, HDL, LDL, TG in the morning after an overnight fast
Arciero et al. (2006) [8]	USA	36 sedentary, overweight/obese men and women, 26 to 60 yrs of age, assigned to an exercise and diet ($n = 19$) or nonintervention control group ($n = 17$)	12 wks of supervised aerobic exercise, 4–6x wk, 30–60 min/d, 50%–75% MHR	Carbohydrate, 55%–60% of kcal; protein 10–15%; fat, <30%	TC, HDL, TC/HDL, LDL, TG in the morning after a 12 hr overnight fast; LDL estimated using the Friedwald formula
Avila and Hovell (1994) [9]	USA	44 overweight Latino women 18 yrs of age and older assigned to an exercise and diet ($n = 22$) or control ($n = 22$) group	8 wks of supervised walking, 1x per wk, 20-min/d; participants also encouraged to walk an additional 15–20 min/d, every d	Carbohydrate, 58% of kcal; protein, 12%; fat, <30%; 1200–1500 kcal/d	TC
Hagan et al. (1986) [10]	USA	24 sedentary, overweight men and women assigned to an exercise and diet ($n = 12$) or control ($n = 12$) group	12 wks of supervised walking and/or running, 30 min/d, 5x per wk	1200 kcal/d	TC, HDL, LDL, TG after a 14 hr fast and 30 min of supine rest; LDL estimated using the Friedwald formula
Hirose et al. (2002) [11]	Japan	35 overweight women >30 yrs of age assigned to either a diet and exercise ($n = 23$) or control ($n = 12$) group	12 wks of unsupervised walking, at least 2x wk, 30 min/d; given a pedometer and asked to walk 10,000 steps/d	1600 kcal/d, <25% fat	TC, HDL, TG
Hopewell (1989) [12]	USA	21 sedentary, overweight, nonsmoking, premenopausal women, 20–51 yrs of age, assigned to an exercise and diet ($n = 11$) or control ($n = 10$) group	24 wks supervised walking, 3x wk, 50 min/d	1200 kcal/d, 60% carbohydrates, 20% protein, 20% fat, 25 g fiber/d	TC, HDL, TC/HDL, LDL, TG after a 12 hr fast and avoiding exercise for at least 24 hr; LDL estimated using the Friedwald formula
McAuley et al. (2002) [13]	New Zealand	54 sedentary, overweight/obese men and women 30–68 yrs of age assigned to a modest exercise and diet ($n = 31$) or control ($n = 23$) group	16 wks supervised & unsupervised aerobic exercise, 5x wk, 30 min/d	<32% of total kcal from fat, $\leq 11\%$ of total kcal from saturated fat, 14% from monounsaturated fat, 7% from polyunsaturated fat, 50% from carbohydrates, 18% from protein, <200 mg cholesterol and >25 g fiber per/d	Fasting TC, HDL, LDL, TG

TABLE 1: Continued.

Study	Country	Group characteristics*	Exercise intervention	Diet intervention	Lipid assessment
Miller et al. (2002) [14]	USA	44 hypertensive, overweight adults, 22 to 70 yrs of age, assigned to either an exercise and diet ($n = 22$) or control ($n = 23$) group	9 wks of supervised aerobic exercise (walking or cycle ergometry), 3x wk, 30–45 min/d, 50%–75% MHR	Hypocaloric version (2100 kcal) of DASH diet (18% kcal from protein, 55% from carbohydrate, 6% saturated fat, 13% monounsaturated fat, 8% polyunsaturated fat, 500 mg/d magnesium, 1240 mg/d calcium, 4700 mg/d potassium, 31 g/d fiber, 150 mg/d cholesterol, 100 mmol/d sodium)	TC, HDL, LDL, TG after fasting; LDL estimated using the Friedwald formula
Nieman et al. (2002) [15]	USA	44 sedentary obese women, 25–75 yrs of age, assigned to either an exercise and diet ($n = 22$) or attention control stretching ($n = 22$) group	12 wks walking, 5x wk (4 supervised, 1 unsupervised), 45 min/d, 60% to 80% MHR	1200–1300 kcal, NCEP Step 1 diet (55% carbohydrate, 30% total fat, $\leq 10\%$ saturated fat, < 300 mg/d of cholesterol)	TC, HDL, TC/HDL, LDL, TG
Wing et al. (1998) [16]	USA	77 overweight men and women, 40–55 yrs of age, assigned to either an exercise and diet ($n = 37$) or control ($n = 40$) group	104 wks supervised and unsupervised brisk walking, increasing to 3 miles per/d, 5x week	800–1,500 kcal/d, 20% of kcal from fat	Fasting TC, HDL, LDL, TG
Wood et al. (1991) [17]	USA	160 sedentary, overweight men and women 25 to 49 yrs of age assigned to either an exercise and diet ($n = 81$) or control ($n = 79$) group	52 wks supervised brisk walking and jogging, 25–45 min/d, 3x wk, 60% to 80% MHR	NCEP Step 1 diet (55% carbohydrate, 30% total fat, $\leq 10\%$ saturated fat, < 300 mg/d of cholesterol)	TC, HDL, LDL, TG in the morning after a 12 to 16 hr overnight fast and avoiding vigorous physical activity for at least 12 hr

Notes. Description of groups and all other variables limited to those that met the criteria for inclusion. *Number of participants include those that began the study but not necessarily included in the final analysis. USA, United States of America; yrs, years; wk, week; wks, weeks; min, minutes; kcal, kilocalories; kg, kilograms; TC, total cholesterol; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; TG, triglycerides; TC/HDL, ratio of total cholesterol to high-density lipoprotein cholesterol; hr, hour; MHR, maximum heart rate; kcal/d, kilocalories per day; min/d, minutes per day; NCEP, National Cholesterol Education Program; mg/d, milligrams per day; VO_{2max} , maximum oxygen consumption; DASH, Dietary Approaches to Stop Hypertension; AHA, American Heart Association; MWC, maximal work capacity.

FIGURE 1: Flow diagram for the selection of studies.

Information on prescription medication use was reported by six studies [6, 7, 9, 13, 14, 17]. Three reported that all participants were taking some type of prescription drug during the study [6, 7, 14], one reported that some were taking medication [13], while another reported that with the exception of hormone replacement therapy, none were taking medication [9]. Another study reported that none of the participants were taking any medications known to affect blood pressure or lipid metabolism [17]. Prescription

drug use included lipid medications, diuretics, beta-blockers, alpha-blockers, calcium channel blockers and angiotensin receptor blockers [14], calcium antagonists, beta-blockers, diuretics, and angiotensin converting enzyme inhibitors [7] or insulin and oral agents [6]. One study reported that participants were allowed to continue their medication use during the study as long as they had been taking them for at least six months and were unlikely to change their intake [13]. Two studies reported that none of the women were

FIGURE 2: Risk of bias assessment.

TABLE 2: Initial characteristics of participants.

Variable	Exercise				Control			
	#	$\bar{X} \pm SD$	Range	Mdn	#	$\bar{X} \pm SD$	Range	Mdn
Age (years)	13	46.3 $\pm$ 8.6	34–62	46.0	13	45.6 $\pm$ 8.7	33–61	45
Body weight (kg)	12	87.5 $\pm$ 34.9	66–99	92.39	12	88.2 $\pm$ 12.1	66–103	91.3
BMI (kg·m ²)	8	31.8 $\pm$ 3.2	27–36	32.7	8	32.4 $\pm$ 3.9	26–37	33.7
VO _{2max} (mL·kg ⁻¹ ·min ⁻¹)	7	28.5 $\pm$ 6.2	20–36	29.4	7	28.5 $\pm$ 6.3	21–38	29.0
Kilocalories (total)	8	2018 $\pm$ 319	1488–2616	1999	8	1950 $\pm$ 353	1398–2616	1922
Carbohydrates (%)	5	49.6 $\pm$ 1.8	48–53	49.0	5	49.7 $\pm$ 2.8	47–54	48.4
Total fat (%)	8	32.4 $\pm$ 3.7	28–38	32	8	32.7 $\pm$ 3.7	27–38	32.6
Saturated fat (%)	5	12.6 $\pm$ 1.8	10–14	13.6	5	12.4 $\pm$ 2.2	9–14	13.6
Cholesterol (mg)	5	318 $\pm$ 61	248–400	296	5	280 $\pm$ 78	197–400	284
TC (mg/dL)	14	212.5 $\pm$ 24.7	188–271	202.2	14	204.3 $\pm$ 16.4	185–238	201.3
HDL-C (mg/dL)	13	48.8 $\pm$ 6.5	38–58	49.0	13	48.0 $\pm$ 6.6	38–58	49.9
TC:HDL-C	5	4.8 $\pm$ 0.6	4.1–5.3	4.9	5	4.8 $\pm$ 0.5	4.1–5.2	4.9
LDL-C (mg/dL)	8	133.4 $\pm$ 17.1	115–172	127.0	8	131.1 $\pm$ 12.9	117–156	126.5
TG (mg/dL)	12	103.7 $\pm$ 55.0	33–224	84.9	12	102.7 $\pm$ 46.2	33–166	102.8

Notes. #, number of groups in which data were available. With the exception of age, data limited to those in which change outcome results could be calculated. Mdn, median; BMI, body mass index; VO_{2max}, maximum oxygen consumption; mg, milligrams; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; TC:HDL-C, ratio of TC to HDL; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides. To convert TC, HDL-C and LDL-C from mg/dL to mmol, divide by 38.46, to convert TG from mg/dL to mmol, divide by 87.72. Insufficient data (<5) reported for protein, polyunsaturated fat, saturated fat, and trans-fat intake as well as non-HDL-C.

taking any type of hormone replacement therapy during the study [12, 17] while another reported that some were taking hormone replacement therapy [9].

Data on cigarette smoking was reported by seven studies [6–8, 12, 14, 15, 17] with four reporting that none of the participants smoked [8, 12, 15, 17] and three reporting that some smoked [6, 7, 14]. For alcohol consumption, one study reported that none of the participants consumed alcohol [10] while two others reported that some did [13, 14]. Eight studies reported that participants were sedentary prior to study enrollment [7–10, 12, 13, 15, 17]. Little information was provided on whether the participants changed their level of physical activity beyond that prescribed to the intervention group. One study did report a decrease in physical activity among participants in the control group [6]. For those studies that included women, five included

both pre- and postmenopausal females [8, 13–16], two were limited to premenopausal women [12, 17], and one was limited to postmenopausal women [6]. At least 10 of the 12 studies included some participants who were hyperlipidemic [6, 7, 9–12, 14–17]. Seven studies reported that none of the participants had type 2 diabetes [8, 10, 13–16] while one reported that all did [6]. Eight of the studies reported that none of the participants had Type 1 diabetes [6–8, 10, 13–16]. In relation to hypertension, two studies reported that all participants were hypertensive [7, 14], one reported that some were [6], and one reported that none were [10]. Five studies reported that none of the participants had a previous history of cardiovascular disease [7, 8, 10, 14, 15], one reported no previous history of stroke [7], another reported no history of metabolic syndrome [8], and another reported no previous history of cancer [15].

3.4. Aerobic Exercise and Diet Interventions

3.4.1. Aerobic Exercise. A description of the aerobic exercise component of the intervention is shown in Table 1. Intervention length ranged from 8 to 208 weeks ($\bar{X} \pm \text{SD}$, 39 ± 56 , Mdn, 12) while the between-group frequency of aerobic training ranged from 2 to 6 sessions per week ($\bar{X} \pm \text{SD}$, 4 ± 1 , Mdn, 3) [6–17]. Within-group frequency of training ranged from 1 to 7 sessions per week for the three studies in which information was available [6, 8, 9]. For the 6 studies and 7 groups in which data were provided [6, 8, 10–12, 15], the mean between-group duration of training ranged from 20 to 50 minutes per session ($\bar{X} \pm \text{SD}$, 35 ± 10 , Mdn, 30) while the within-group duration ranged from 15 to 60 minutes for the 7 studies and 8 groups that reported such [8, 9, 13–17]. Within-group intensity of training ranged from 50% to 90% of maximum heart rate (MHR) for the 6 studies and 7 groups that reported data [7, 8, 13–15, 17]. Insufficient data were provided to calculate between-group intensity of training. Between-group total minutes of training ranged from 60 to 228 minutes per week ($\bar{X} \pm \text{SD}$, 142 ± 69 , Mdn, 150) for the 6 studies and 7 groups from which data could be calculated [6, 8, 10–12, 15]. The most common types of activities were walking followed by jogging and cycling. Between-group compliance, defined as the percentage of exercise sessions attended, ranged from 38% to 98% for the 5 studies in which adequate data were provided ($\bar{X} \pm \text{SD}$, 78 ± 24 , Mdn, 86) [8, 12, 14–16]. Ten studies representing 12 groups reported exercise data (frequency, intensity, duration) based on what was prescribed versus completed [6, 7, 9–11, 13–17] while two others reported what was actually completed [8, 12]. Five studies comprising 7 groups reported that exercise sessions were supervised [8, 10, 12, 14, 17], 1 reported that exercise was unsupervised [11] while the remaining 6 included both supervised and unsupervised sessions [6, 7, 9, 13, 15, 16].

3.4.2. Diet. A description of the diet interventions employed is shown in Table 1. Two studies representing 3 groups used the National Cholesterol Education Program (NCEP) Step 1 diet [15, 17] while two others used either the American Heart Association (AHA) Step 1 diet [8] or a diet based on previous recommendations from the California Dietetics Association [9]. Diets included caloric restriction only and/or modification of other dietary components (fat, saturated fat, fiber, etc.). Ten studies representing 12 groups reported weight loss as a goal for all participants [6, 8–12, 14–17] while another reported weight loss as a goal for some participants [13]. Another study reported that weight loss was not a goal [7].

3.5. Assessment of Primary Outcomes. Results for lipid and lipoprotein assessment procedures are shown in Table 1. Nine of 12 studies reported that participants fasted prior to the assessment of lipids and lipoproteins [6–8, 10, 12–14, 16, 17] with fasting occurring for at least 12 hours [6–8, 10, 12, 17]. Since the three other studies did not report this information, the investigative team was unable to determine whether the participants fasted [9, 11, 15]. For the 8 studies in which data were available, all reported that assessment

took place in the morning [6–8, 10, 12–14, 17]. Three studies reported that exercise was avoided for at least 12 hours prior to lipid assessment [8, 12, 17]. One study reported that lipid and lipoprotein assessment took place between August and April [12].

3.6. Assessment of Secondary Outcomes. For those studies in which data were available, bodyweight was assessed using either standard or electronic scales [6, 8, 9, 11–14, 16, 17]. Maximum oxygen consumption ($\text{VO}_{2\text{max}}$ in $\text{mL} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$) was measured using either a graded, maximal [10, 17], or submaximal [13] treadmill test or estimated from a walk test [9, 16].

For those studies that reported data, a variety of methods were used for assessing nutrient intake. These included a 1-week food frequency questionnaire [6], 3-day food record [8, 10], 3-day food record and 24 hour recall [15], 3-day food record and block food frequency questionnaire [16], 4-day food record [13] self-reported and interviewer administered 7-day food records [17] and a semiquantitative food frequency questionnaire [11].

3.7. Pooled Estimates of ES

3.7.1. Primary Outcomes. Overall group-level changes in lipid and lipoprotein concentrations are shown in Table 3 and Figures 3, 4, 5, 6, and 7. One outlier for changes in TC was deleted from the model [9]. Statistically significant intervention minus control improvements were found for TC, TC:HDL-C, LDL-C, and TG, but not for HDL-C. Changes were equivalent to relative improvements of 6.0%, 10.4%, 5.1%, and 12.6%, respectively, for TC, TC:HDL-C, LDL-C, and TG. A nonsignificant decrease of 0.8% was observed for HDL-C. A medium to large amount of heterogeneity was found for all lipid and lipoprotein outcomes and all prediction intervals encompassed zero (0). When adjusted for publication bias, changes in TG remained significant ($\bar{X}$, -10.3 mg/dL , 95% CI, $-18.9, -1.8$). No adjustment for publication bias was needed for any other lipid and lipoprotein outcome. With each study deleted from the model once, the significance/nonsignificance of results did not change. Cumulative meta-analysis, ranked by year, demonstrated that changes have remained significant since 1989 for TC, 1991 for TC:HDL-C and TG, 2002 for LDL-C while changes in HDL-C have continued to be nonsignificant since the first included study in 1986. The direction of results did not change when studies with multiple groups were collapsed so that only one ES represented each study (Table 4). However, the amount of heterogeneity was reduced to a nonsignificant value for TC:HDL-C.

Meta-regression results are shown in Table 5. For TC, shorter interventions and greater decreases in body weight and BMI were associated with larger reductions in TC. Greater increases in HDL-C were associated with larger increases in $\text{VO}_{2\text{max}}$ and greater decreases in kilocalories. For TC:HDL-C, larger decreases were associated with being male, having higher baseline values of TC:HDL-C and greater reductions in bodyweight and kilocalories. Greater reductions in LDL-C were correlated with shorter

FIGURE 3: Forest plot for changes in TC (mg/dL).

FIGURE 4: Forest plot for changes in HDL-C (mg/dL).

interventions as well as larger decreases in bodyweight and BMI. Larger reductions in TG were associated with younger age, higher initial TG levels, and greater decreases in bodyweight. No other statistically significant associations were observed.

3.7.2. Secondary Outcomes. Overall group-level changes for body weight, BMI, cardiorespiratory fitness, and diet outcomes are shown in Table 3. Statistically significant intervention minus control group improvements were found for bodyweight, BMI, VO_{2max} in $mL \cdot kg^{-1} \cdot min^{-1}$, kilocalories, carbohydrates, total fat, saturated fat, and chole-

sterol intake. Changes were equivalent to relative improvements of 6.1%, 4.4%, 15.9%, 18.9%, 5.7%, 11.7%, 26.8%, and 41.6%, respectively, for bodyweight, BMI, VO_{2max} in $mL \cdot kg^{-1} \cdot min^{-1}$, kilocalories, carbohydrates, total fat, saturated fat, and cholesterol intake. A small amount of heterogeneity was found for changes in BMI, kilocalories, and cholesterol intake while a large amount was observed for body weight, VO_{2max} in $mL \cdot kg^{-1} \cdot min^{-1}$, carbohydrates, total fat and saturated fat intake. Nonoverlapping prediction intervals for estimating what results could have been expected if a new trial was conducted were observed for BMI, kilocalories and cholesterol intake. Prediction intervals

FIGURE 5: Forest plot for changes in TC : HDLC.

FIGURE 6: Forest plot for changes in LDL-C (mg/dL).

for all other secondary outcomes included zero (0). No adjustment for publication bias was needed for any secondary outcomes. With each study deleted from the model once, results remained significant for body weight, BMI, relative $\text{VO}_{2\text{max}}$, kilocalories, total fat, saturated fat, and cholesterol but not for carbohydrates. Cumulative meta-analysis, ranked by year, demonstrated that changes have remained significant since 1986 for body weight and $\text{VO}_{2\text{max}}$ in $\text{mL}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$, 1991 for kilocalorie and cholesterol intake, 1994 for BMI, 2002 for total and saturated fat, and 2005 for carbohydrates. When studies with multiple groups were collapsed so that only one ES represented each study, overall changes as well as heterogeneity and prediction intervals did not change significantly for any of the outcomes (Table 4). Meta-regression results revealed no statistically significant association between gender and changes in body weight, (β_1 , 1.0, 95% CI, -6.9, 8.8), kilocalories (β_1 , 168,

95% CI, -176, 513), total fat (β_1 , 0.2, 95% CI, -9.3, 9.7), or saturated fat (β_1 , 0.2, 95% CI, -9.3, 9.7). Greater reductions in cholesterol intake were associated with being male (β_1 , 77.2, 95% CI, 5.2, 149.2).

4. Discussion

The current findings suggest that concurrent aerobic exercise and diet are associated with improvements in TC, TC : HDL-C, LDL-C, and TG, but not HDL-C in overweight and obese adults. Given the low baseline levels, the decreases observed for TG may be especially noteworthy. The lack of increase in HDL-C, despite an increase in aerobic capacity, may have been the result of decreases in total fat intake and weight loss. However, this would need to be tested in a large, well-designed, randomized controlled trial before any firm conclusions could be drawn.

FIGURE 7: Forest plot for changes in TG (mg/dL).

TABLE 3: Changes in primary and secondary outcomes (group level).

Variable	Studies (#)	Participants (#)	ES (#)	$\bar{X}$ (95% CI)	$Q(P)$	I^2 (%)	95% PI
Primary outcomes							
TC (mg/dL)	11	820	13	-12.8 (-19.9, -5.7)*	65.2 (<0.001)*	81.6	-38.6, 13.1
HDL-C (mg/dL)	11	820	13	-0.4 (-2.3, 1.6)	60.6 (<0.001)*	80.2	-7.6, 6.8
TC:HDL-C	6	383	8	-0.5 (-0.8, -0.1)*	46.6 (<0.001)*	85.0	-1.7, 0.7
LDL-C (mg/dL)	10	783	12	-6.8 (-11.8, -1.8)*	36.8 (<0.001)*	70.0	-23.3, 9.7
TG (mg/dL)	11	820	13	-13.1 (-21.3, -5.0)*	59.2 (<0.001)*	79.7	-39.1, 12.9
Secondary outcomes							
Body weight (kg)	10	423	12	-5.2 (-7.3, -3.0)*	134.2 (<0.001)*	91.8	-13.3, 3.0
BMI (kg/m ²)	8	197	8	-1.4 (-1.7, -1.0)*	10.7 (0.2)	34.4	-2.2, -0.53*
VO _{2max} (mL·kg ⁻¹ ·min ⁻¹)	5	182	7	4.8 (2.0, 7.6)*	123.9 (<0.001)*	95.2	-5.3, 14.9
Kilocalories (total)	6	389	7	-417 (-515, -320)*	7.7 (0.3)	21.6	-619, -216*
Carbohydrates (%)	5	240	5	2.8 (0.8, 4.7)*	88.1 (<0.001)*	95.5	-4.3, 9.9
Total fat (%)	7	343	8	-4.1 (-6.3, -1.8)*	286.2 (<0.001)*	97.6	-12.0, 3.9
Saturated fat (%)	4	160	5	-6.2 (-5.4, -0.9)*	246.1 (<0.001)*	98.4	-13.9, 6.9
Cholesterol (mg)	4	153	5	-130 (-165, -96)*	5.8 (0.2)	31.6	-221, -40*

Notes. ES, effect sizes; #, number for which data were available; $\bar{X}$ (95% CI), mean and 95% confidence interval; $Q(P)$, Cochran's Q statistic for heterogeneity and alpha value; I^2 (%), percent inconsistency statistic; 95% PI, 95% prediction intervals for a new study; *, statistically significant; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; TC:HDL-C, TC:HDL-C ratio; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides; BMI, body mass index; VO_{2max}, maximum oxygen consumption; %, percentage of total kilocalorie intake. To convert TC, HDL-C, and LDL-C from mg/dL to mmol, divide by 38.46; to convert TG from mg/dL to mmol, divide by 87.72.

Improvements remained robust when each study was deleted from the model once. In addition, results have been statistically significant since at least 2002. Furthermore, these findings appear to be more pronounced than those achieved with aerobic exercise or diet alone. For example, previous meta-analytic work addressing the independent effects of aerobic exercise on lipid and lipoprotein concentrations in overweight and obese adults reported statistically significant decreases in TG but not TC, HDL-C or LDL-C after sensitivity analyses were applied [36]. Another meta-analysis

that examined the effects of cholesterol-lowering diets on TC alone reported a statistically significant reduction of 5.7% [37]. This compares to the approximate 8.2% reduction observed in the current investigation. However, this prior meta-analysis did not appear to be limited to overweight and obese adults and excluded trials aimed primarily at lowering body weight [37].

The findings of the current investigation appear to be clinically important. Using data from previous research, the improvements in lipids and lipoproteins observed in the

TABLE 4: Changes in primary and secondary outcomes (study level).

Variable	Studies (#)	Participants (#)	ES (#)	$\bar{X}$ (95% CI)	$Q(P)$	I^2 (%)	95% PI
Primary outcomes							
TC (mg/dL)	11	820	11	-12.6 (-20.1, -5.1)*	60.5 (<0.001)*	83.5	-38.8, 13.6
HDL-C (mg/dL)	11	820	11	-0.8 (-2.8, 1.2)	53.0 (<0.001)*	81.1	-21.3, 19.7
TC:HDL-C	6	383	6	-0.5 (-0.7, -0.3)*	9.1 (0.11)	45.0	-1.1, 0.1
LDL-C (mg/dL)	10	783	10	-6.8 (-11.8, -1.8)*	30.4 (<0.001)*	70.4	-22.6, 9.1
TG (mg/dL)	11	820	11	-10.6 (-18.8, -2.4)*	48.1 (<0.001)*	79.2	-35.4, 14.3
Secondary outcomes							
Body weight (kg)	10	423	10	-4.3 (-6.6, -2.0)*	125.3 (<0.001)*	92.8	-12.7, 4.0
BMI (kg/m ²)	8	197	8	-1.4 (-1.7, -1.0)*	10.7 (0.2)	34.4	-2.2, -0.53*
VO _{2max} (mL·kg ⁻¹ ·min ⁻¹)	5	182	5	3.6 (0.3, 7.0)*	121.4 (<0.001)*	96.7	-9.4, 16.6
Kilocalories (total)	6	389	6	-405 (-512, -298)*	7.3 (0.2)	32.0	-660, -150*
Carbohydrates (%)	5	240	5	2.8 (0.8, 4.7)*	88.1 (<0.001)*	95.5	-4.3, 9.9
Total fat (%)	7	343	7	-3.5 (-5.8, -1.1)*	284.7 (<0.001)*	97.9	-11.9, 4.9
Saturated fat (%)	4	160	4	-3.5 (-6.4, -0.5)*	245.8 (<0.001)*	98.8	-17.9, 11.0
Cholesterol (mg)	4	153	4	-127 (-153, -101)*	1.1 (0.8)	0	-185, -69*

Notes. ES, effect sizes; #, number for which data were available; $\bar{X}$ (95% CI), mean and 95% confidence interval; $Q(P)$, Cochran's Q statistic for heterogeneity and alpha value; I^2 (%), percent inconsistency statistic; 95% PI, 95% prediction intervals for a new study; *, statistically significant; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; TC:HDL-C, TC:HDL-C ratio; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides; BMI, body mass index; VO_{2max}, maximum oxygen consumption; %, percentage of total kilocalorie intake. To convert TC, HDL-C, and LDL-C from mg/dL to mmol, divide by 38.46; to convert TG from mg/dL to mmol, divide by 87.7.

current meta-analysis would be equivalent to relative risk reductions in all-cause and coronary heart disease mortality of 5.7% and 8.0%, respectively, for TC and 2.8% and 5.0% for LDL-C [38] while reductions in TC:HDL-C would equate to an approximate 12.4% decrease in the relative risk of mortality from ischemic heart disease [39]. For TG, the observed decreases would be equivalent to a relative risk reduction of 6.4% in coronary heart disease mortality [40]. The decreases observed for LDL-C may be especially important given that LDL-C is currently the primary target of lipid-lowering therapy in adults [5].

Although the overall results of the current meta-analysis suggest that a combined program of aerobic exercise and diet improves TC, TC:HDL-C, LDL, and TG, a moderate to large amount of heterogeneity and inconsistency was observed for all lipid and lipoprotein outcomes. Given these findings and despite the fact that a random-effects model that incorporates heterogeneity into the analysis was used, the generalization of results may not be appropriate [27]. However, the use of such statistics to decide what comprises true heterogeneity and inconsistency is rather arbitrary in nature, and thus, should be viewed with caution [41]. Another issue has to do with the fact that all prediction intervals for estimating the expected results of a new trial included zero for all lipid and lipoprotein outcomes. However, these values should not be confused with confidence intervals since prediction intervals are based on a random mean effect while confidence intervals are not [35].

Meta-regression analyses resulted in several statistically significant associations, most notably, the association between decreases in bodyweight with reductions in TC, TC:HDL-C, LDL-C, and TG. However, while an important first step, all reported meta-regression analyses should be viewed with caution. For example, the investigative team was unable to conduct any type of multiple meta-regression

analyses because of the small number of ESs as well as missing data for different variables from different studies, a common occurrence in meta-analysis. Consequently, the potential for confounding exists. In addition, because of the large number of statistical tests conducted, one or more of the statistically significant findings could have been due to chance. Given the former, the validity of the associations observed in the current meta-analysis would need to be tested in large, well-designed randomized controlled trials.

The significant changes observed for bodyweight and BMI as well as VO_{2max} in mL·kg⁻¹·min⁻¹ suggest that a combined aerobic exercise and diet regimen results in improvements beyond those for lipid and lipoprotein concentrations in overweight and obese adults. This reinforces the investigative team's perspective that it is highly unlikely that any pharmacologic intervention will ever be developed that targets as many risk factors as a combined program of aerobic exercise and diet. In addition, aerobic exercise and diet may synergistically improve the effects pharmacologic therapies such as HMG-CoA reductase inhibitors (statins) [5]. Finally, the significant reductions observed for kilocalories, total fat, saturated fat, and cholesterol suggest good adherence to the different diet regimens employed.

The small amount of heterogeneity and inconsistency as well as non-overlapping prediction intervals for BMI, kilocalories, and cholesterol intake provide greater credence and applicability of these outcomes with respect to the effects of aerobic exercise and diet in overweight and obese adults. For example, prediction intervals may be more relevant from a practical perspective since they provide an approximation of the expected treatment effect in a new trial [35]. However, the representativeness of the results for all secondary outcome analyses may need to be interpreted with caution since they were only included if data for the primary outcomes (lipids and lipoproteins) were available.

TABLE 5: Metaregression results for changes in lipid and lipoprotein concentrations.

Variable	Studies (#)	Participants (#)	ES (#)	β_1 (95% CI)	R	R ²
TC						
Age (years)	10	810	12	0.4 (−0.4, 1.3)	.33	.11
Gender	6	574	8	−0.57 (−20.9, 19.8)	.03	<.01
Initial TC (mg/dL)	11	820	13	0.2 (−0.2, 0.5)	.28	.08
Intervention (wks)	11	820	13	0.1 (0.05, 0.2)*	.74	.55
Δ Body weight (kg)	9	758	10	2.1 (0.8, 3.5)*	.73	.54
Δ BMI (kg/m ²)	7	325	7	10.1 (3.2, 17.0)*	.83	.69
Δ VO _{2max} (mL·kg ^{−1} ·min ^{−1})	5	313	7	−0.9 (−3.4, 1.6)	.31	.10
Δ Kilocalories	6	389	7	0.02 (−0.03, 0.06)	.32	.10
Δ Total fat (%)	7	654	8	0.9 (−0.4, 2.2)	.56	.31
Δ Saturated fat (%)	4	304	5	0.4 (−3.5, 4.3)	.12	.02
Δ Cholesterol (mg)	4	292	5	−0.1 (−0.3, 0.2)	.27	.07
HDL-C						
Age (years)	10	810	12	−0.2 (−0.4, 0.1)	.41	.17
Gender	6	574	8	−4.0 (−8.9, 0.9)	.62	.38
Initial HDL-C (mg/dL)	11	820	13	−0.1 (−0.4, 0.2)	.20	.04
Intervention (wks)	11	820	13	0.01 (−0.03, 0.05)	.18	.03
Δ Body weight (kg)	10	810	12	−0.5 (−1.0, 0.1)	.52	.27
Δ BMI (kg/m ²)	7	325	7	0.7 (−1.9, 3.4)	.25	.06
Δ VO _{2max} (mL·kg ^{−1} ·min ^{−1})	4	313	6	0.9 (0.2, 1.5)*	.75	.56
Δ Kilocalories	6	389	7	−0.02 (−.04, −0.001)*	.73	.53
Δ Total fat (%)	7	654	8	−0.2 (−0.8, 0.4)	.25	.06
Δ Saturated fat (%)	4	304	5	0.6 (−1.6, 2.8)	.44	.19
Δ Cholesterol (mg)	4	292	5	−0.05 (−0.1, 0.03)	.54	.29
TC:HDL-C						
Age (years)	6	383	8	0.02 (−0.02, 0.06)	.30	.09
Gender	3	252	5	0.9 (0.5, 1.2)*	.93	.87
Initial TC:HDL (mg/dL)	4	180	5	−0.9 (−1.6, −0.1)*	.77	.60
Intervention (wks)	6	383	8	−0.01, (−0.03, 0.01)	.28	.08
Δ Body weight (kg)	6	383	8	0.1 (0.1, 0.2)*	.81	.66
Δ BMI (kg/m ²)	4	175	4	0.1 (−0.2, 0.5)	.81	.66
Δ VO _{2max} (mL·kg ^{−1} ·min ^{−1})	2	208	4	−0.2 (−0.9, 0.4)	.38	.14
Δ Kilocalories	4	292	5	0.005 (0.002, 0.007)*	.92	.85
Δ Total fat (%)	4	292	5	0.01 (−0.02, 0.1)	.74	.54
Δ Saturated fat (%)	3	261	4	0.1 (−0.2, 0.4)	.51	.26
Δ Cholesterol (mg)	4	292	5	−0.0002 (−0.002, 0.002)	.12	.02
LDL-C						
Age (years)	9	773	11	0.4 (−0.1, 1.0)	.43	.18
Gender	4	262	6	3.2 (−10.5, 17.0)	.21	.04
Initial LDL-C (mg/dL)	10	783	12	0.3 (−0.02, 0.52)	.49	.24
Intervention (wks)	10	783	12	0.06 (0.01, 0.12)*	.58	.34
Δ Body weight (kg)	9	773	11	1.4 (0.5, 2.4)*	.67	.45
Δ BMI (kg/m ²)	6	290	6	8.6 (2.5, 14.6)*	.81	.66
Δ VO _{2max} (mL·kg ^{−1} ·min ^{−1})	4	313	6	−1.1 (−3.0, 0.8)	.46	.21
Δ Kilocalories	5	355	6	0.02 (−0.02, 0.07)	.50	.25
Δ Total fat (%)	6	620	7	0.5 (−0.6, 1.5)	.39	.15
Δ Saturated fat (%)	4	304	5	0.2 (−2.7, 3.2)	.09	.01
Δ Cholesterol (mg)	4	292	5	−0.004 (−0.2, 0.2)	.03	>.01

TABLE 5: Continued.

Variable	Studies (#)	Participants (#)	ES (#)	β_1 (95% CI)	R	R ²
TG						
Age (years)	10	810	12	1.5 (0.3, 2.7)*	0.53	0.28
Gender	6	574	8	6.2 (−21.7, 34.0)	0.13	0.02
Initial TG (mg/dL)	10	777	12	−0.3 (−0.6, −0.1)*	0.62	0.38
Intervention (wks)	11	820	13	0.1 (−0.1, 0.2)	0.17	0.03
Δ Body weight (kg)	10	810	12	3.2 (1.1, 5.4)*	0.59	0.35
Δ BMI (kg/m ²)	7	325	7	0.2 (−21.2, 21.6)	.01	<.001
Δ VO _{2max} (mL·kg ^{−1} ·min ^{−1})	4	313	6	−3.1 (−7.3, 1.2)	.49	.24
Δ Kilocalories	6	389	7	−0.02 (−0.1, 0.1)	.18	.03
Δ Total fat (%)	6	620	7	1.5 (−0.4, 3.4)	.57	.33
Δ Saturated fat (%)	4	304	5	−2.7 (−8.5, 3.0)	.51	.26
Δ Cholesterol (mg)	4	292	5	−0.1 (−0.2, 0.4)	.39	.15

Notes. ES, effect sizes; #, number for which data were available; Δ, ES change for outcome; β_1 (95% CI), slope and 95% confidence interval; *, statistically significant.

The overall reporting and conduct of randomized controlled trials on this topic could be improved. First, information on study design characteristics, including allocation concealment, incomplete data (dropouts, reasons for dropping out, adverse events), and incomplete outcome reporting should be provided. For incomplete outcome reporting, the inclusion of the study identification protocol number would be especially helpful to readers. In addition, since part of the intervention includes exercise, only those participants not engaged in a regular exercise program prior to enrollment should be included since prior exercise may diminish the effects of the intervention. Furthermore, all of the studies used a per-protocol approach in the analysis of their data. Given the former, the investigative team suggests that future studies report data using both the per-protocol and intention-to-treat approach. Second, the reporting of selected participant characteristics could be improved. This includes data on race/ethnicity, medication use before and during the intervention, cigarette smoking, and alcohol consumption, as well as any changes in physical activity, void of the exercise intervention, which occurred during the study. Third, in order to examine dose-response effects, additional information regarding the aerobic exercise and diet intervention should be provided. For aerobic exercise, data on the duration and intensity of the intervention as well as compliance to the exercise protocol should be provided. In addition, the provision of data on energy expenditure is also recommended. With respect to the diet intervention, complete data should be provided on the intake of kilocalories, protein, total fat, saturated fat, transfat, and cholesterol. Fourth, additional lipid assessment data that includes the number of hours in which subjects refrained from exercise prior to lipid testing, season(s) in which lipids were assessed and whether assessment of LDL-C occurred using the direct or indirect method should be included. Fifth, since non-HDL-C has been shown to be a better predictor of cardiovascular morbidity and mortality than LDL-C [42, 43], the calculation of non-HDL-C from TC and HDL-C, including dispersion statistics is recommended. Given their

potential association with changes in lipid and lipoprotein concentrations, data on percent body fat as well as lean body mass would also be helpful.

Finally, the primary purpose of this important meta-analysis was to focus on the *combined* versus independent effects of aerobic exercise and diet on lipids and lipoproteins in overweight and obese adults. The rationale for this approach was based on the fact that both are recommended in tandem for improving the lipid-lipoprotein profile of adults [5]. Given this study design, we were unable to determine the independent effects of each on the lipid-lipoprotein profile. Therefore, future meta-analytic research should examine the independent effects of aerobic exercise and diet for improving the lipid-lipoprotein profile of overweight and obese adults.

In conclusion, the overall results of this study suggest that a combined program of aerobic exercise and diet is associated with improvements in TC, LDL-C, TC:HDL-C and TG, but Not HDL-C, in overweight and obese adults. However, additional, well-designed randomized controlled trials on this topic are needed.

Conflict of Interests

The authors declare no conflict of interests.

Acknowledgment

This study was supported by Grant R01 HL069802 from the National Institutes of Health, National Heart, Lung, and Blood Institute (G. A. Kelley, principal investigator).

References

- [1] World Health Organization, Obesity and Overweight, 2011, <http://www.who.int/mediacentre/factsheets/fs311/en/index.html>.
- [2] C. L. Ogden and M. D. Carroll, *Prevalence of Overweight, Obesity, and Extreme Obesity Among Adults: United States, Trends*

- 1976–1980 Through 2007–2008, National Center for Health Statistics, 2010.
- [3] D. Lloyd-Jones, R. J. Adams, T. M. Brown et al., “Executive summary: heart disease and stroke statistics-2010 update: a report from the american heart association,” *Circulation*, vol. 121, no. 7, pp. e46–e215, 2010.
  - [4] A. H. Mokdad, E. S. Ford, B. A. Bowman et al., “Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001,” *Journal of the American Medical Association*, vol. 289, no. 1, pp. 76–79, 2003.
  - [5] National Cholesterol Education Program, National Heart Lung and Blood Institute and National Institutes of Health, “Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report,” *Circulation*, vol. 106, pp. 3143–3421, 2002.
  - [6] T. D. Agurs-Collins, S. K. Kumanyika, T. R. Ten Have, and L. L. Adams-Campbell, “A randomized controlled trial of weight reduction and exercise for diabetes management in older African-American subjects,” *Diabetes Care*, vol. 20, no. 10, pp. 1503–1511, 1997.
  - [7] S. A. Anderssen, A. K. Hjelstuen, I. Hjermann, K. Bjerkan, and I. Holme, “Fluvastatin and lifestyle modification for reduction of carotid intima-media thickness and left ventricular mass progression in drug-treated hypertensives,” *Atherosclerosis*, vol. 178, no. 2, pp. 387–397, 2005.
  - [8] P. J. Arciero, C. L. Gentile, R. Martin-Pressman et al., “Increased dietary protein and combined high intensity aerobic and resistance exercise improves body fat distribution and cardiovascular risk factors,” *International Journal of Sport Nutrition and Exercise Metabolism*, vol. 16, no. 4, pp. 373–392, 2006.
  - [9] P. Avila and M. F. Hovell, “Physical activity training for weight loss in Latinas: a controlled trial,” *International Journal of Obesity*, vol. 18, no. 7, pp. 476–482, 1994.
  - [10] R. D. Hagan, S. J. Upton, L. Wong, and J. Whittam, “The effects of aerobic conditioning and/or caloric restriction in overweight men and women,” *Medicine and Science in Sports and Exercise*, vol. 18, no. 1, pp. 87–94, 1986.
  - [11] K. Hirose, K. Tajima, and S. Miura, “A model obesity control program focusing on a healthy diet and gentle exercise in Aichi cancer center hospital,” *Asian Pacific Journal of Cancer Prevention*, vol. 3, pp. 149–154, 2002.
  - [12] R. Hopewell, *The effect of fiber and exercise on weight loss and blood lipids in moderately overweight women*, dissertation, West Virginia University, 1989.
  - [13] K. A. McAuley, S. M. Williams, J. I. Mann et al., “Intensive lifestyle changes are necessary to improve insulin sensitivity: a randomized controlled trial,” *Diabetes Care*, vol. 25, no. 3, pp. 445–452, 2002.
  - [14] E. R. Miller, T. P. Erlinger, D. R. Young et al., “Results of the diet, exercise, and weight loss intervention trial (DEW-IT),” *Hypertension*, vol. 40, no. 5, pp. 612–618, 2002.
  - [15] D. C. Nieman, D. W. Brock, D. Butterworth, A. C. Utter, and C. C. Nieman, “Reducing diet and/or exercise training decreases the lipid and lipoprotein risk factors of moderately obese women,” *Journal of the American College of Nutrition*, vol. 21, no. 4, pp. 344–350, 2002.
  - [16] R. R. Wing, E. Venditti, J. M. Jakicic, B. A. Polley, and W. Lang, “Lifestyle intervention in overweight individuals with a family history of diabetes,” *Diabetes Care*, vol. 21, no. 3, pp. 350–359, 1998.
  - [17] P. D. Wood, M. L. Stefanick, P. T. Williams, and W. L. Haskell, “The effects on plasma lipoproteins of a prudent weight-reducing diet, with or without exercise, in overweight men and women,” *The New England Journal of Medicine*, vol. 325, no. 7, pp. 461–466, 1991.
  - [18] L. V. Hedges and I. Olkin, “Vote-counting methods in research synthesis,” *Psychological Bulletin*, vol. 88, no. 2, pp. 359–369, 1980.
  - [19] H. S. Sacks, J. Berrier, and D. Reitman, “Meta-analyses of randomized controlled trials,” *The New England Journal of Medicine*, vol. 316, no. 8, pp. 450–455, 1987.
  - [20] A. Liberati, D. G. Altman, J. Tetzlaff et al., “The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration,” *Annals of Internal Medicine*, vol. 151, no. 4, pp. W-65–W-94, 2009.
  - [21] G. V. Mann, K. Teel, O. Hayes, A. McNally, and D. Bruno, “Exercise in the disposition of dietary calories: regulation of serum lipoprotein and cholesterol levels in human subjects,” *The New England Journal of Medicine*, vol. 253, pp. 349–355, 1955.
  - [22] Physical Activity Guidelines Advisory Committee, *Physical Activity Guidelines Advisory Report*, U.S. Department of Health and Human Services, Washington, DC, USA, 2008.
  - [23] K. F. Schulz, L. Chalmers, R. J. Hayes, and D. G. Altman, “Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials,” *Journal of the American Medical Association*, vol. 273, no. 5, pp. 408–412, 1995.
  - [24] J. D. Emerson, E. Burdick, D. C. Hoaglin, F. Mosteller, and T. C. Chalmers, “An empirical study of the possible relation of treatment differences to quality scores in controlled randomized clinical trials,” *Controlled Clinical Trials*, vol. 11, no. 5, pp. 339–352, 1990.
  - [25] P. Jüni, A. Witschi, R. Bloch, and M. Egger, “The hazards of scoring the quality of clinical trials for meta-analysis,” *Journal of the American Medical Association*, vol. 282, no. 11, pp. 1054–1060, 1999.
  - [26] S. Ahn and B. J. Becker, “Incorporating quality scores in meta-analysis,” *Journal of Educational and Behavioral Statistics*, vol. 36, no. 5, pp. 555–585, 2011.
  - [27] J. P. T. Higgins and S. Green, *2009 Cochrane Handbook for Systematic Reviews of Interventions (version 5.0.2)*, 2009.
  - [28] D. Follmann, P. Elliott, I. Suh, and J. Cutler, “Variance imputation for overviews of clinical trials with continuous response,” *Journal of Clinical Epidemiology*, vol. 45, no. 7, pp. 769–773, 1992.
  - [29] R. DerSimonian and N. Laird, “Meta-analysis in clinical trials,” *Controlled Clinical Trials*, vol. 7, no. 3, pp. 177–188, 1986.
  - [30] J. E. Hunter and F. L. Schmidt, “Fixed effects vs. random effects meta-analysis models: implications for cumulative research knowledge,” *International Journal of Selection and Assessment*, vol. 8, no. 4, pp. 275–292, 2000.
  - [31] W. G. Cochran, “The combination of estimates from different experiments,” *Biometrics*, vol. 10, pp. 101–129, 1954.
  - [32] J. P. T. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, “Measuring inconsistency in meta-analyses,” *British Medical Journal*, vol. 327, no. 7414, pp. 557–560, 2003.
  - [33] S. Duval and R. Tweedie, “Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis,” *Biometrics*, vol. 56, no. 2, pp. 455–463, 2000.
  - [34] J. Lau, C. H. Schmid, and T. C. Chalmers, “Cumulative meta-analysis of clinical trials builds evidence for exemplary medical

- care," *Journal of Clinical Epidemiology*, vol. 48, no. 1, pp. 45–57, 1995.
- [35] J. P. T. Higgins, S. G. Thompson, and D. J. Spiegelhalter, "A re-evaluation of random-effects meta-analysis," *Journal of the Royal Statistical Society Series A*, vol. 172, no. 1, pp. 137–159, 2009.
  - [36] G. A. Kelley, K. S. Kelley, and Z. Vu Tran, "Aerobic exercise, lipids and lipoproteins in overweight and obese adults: a meta-analysis of randomized controlled trials," *International Journal of Obesity*, vol. 29, no. 8, pp. 881–893, 2005.
  - [37] J. L. Tang, J. M. Armitage, T. Lancaster, C. A. Silagy, G. H. Fowler, and H. A. W. Neil, "Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects," *British Medical Journal*, vol. 316, no. 7139, pp. 1213–1219, 1998.
  - [38] A. L. Gould, G. M. Davies, E. Alemao, D. D. Yin, and J. R. Cook, "Cholesterol reduction yields clinical benefits: meta-analysis including recent trials," *Clinical Therapeutics*, vol. 29, no. 5, pp. 778–794, 2007.
  - [39] S. Lewington, G. Whitlock, R. Clarke et al., "Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths," *The Lancet*, vol. 370, pp. 1829–1839, 2007.
  - [40] Y. He, T. H. Lam, L. S. Li, L. S. Li, S. F. He, and B. Q. Liang, "Triglyceride and coronary heart disease mortality in a 24-year follow-up study in Xi'an, China," *Annals of Epidemiology*, vol. 14, no. 1, pp. 1–7, 2004.
  - [41] D. G. Bonett, "Meta-analytic interval estimation for standardized and unstandardized mean differences," *Psychological Methods*, vol. 14, no. 3, pp. 225–238, 2009.
  - [42] Y. Cui, R. S. Blumenthal, J. A. Flaws et al., "Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality," *Archives of Internal Medicine*, vol. 161, no. 11, pp. 1413–1419, 2001.
  - [43] T. Pischon, C. J. Girman, F. M. Sacks, N. Rifai, M. J. Stampfer, and E. B. Rimm, "Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men," *Circulation*, vol. 112, no. 22, pp. 3375–3383, 2005.